Bronconex Acticap

Country: New Zealand

Language: English

Source: Medsafe (Medicines Safety Authority)

Active ingredient:

Mometasone furoate 400ug (anhydrous)

Available from:

Organon (New Zealand) Limited

INN (International Name):

Mometasone furoate 400 µg (anhydrous)

Dosage:

400 mcg/dose

Pharmaceutical form:

Powder for inhalation

Composition:

Active: Mometasone furoate 400ug (anhydrous) Excipient: Lactose

Units in package:

Inhaler, metered, DPI, (sample), 14 dose units

Class:

Prescription

Prescription type:

Prescription

Manufactured by:

MSD International GmbH (Singapore Branch)

Therapeutic indications:

Bronconex Acticap is indicated for prophylactic therapy in the management of patients with asthma of all severities, including patients who have been dependent upon either inhaled or systemically administered corticosteroids and non-corticosteroid-dependent patients inadequately controlled on other drug regimens.

Product summary:

Package - Contents - Shelf Life: Inhaler, metered, DPI, (sample) - 14 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 30 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 60 dose units - 18 months from date of manufacture stored at or below 25°C

Authorization date:

2000-12-05